[ad_1]
CHICAGO, May 4, 2019 / PRNewswire / – Today 's consumer is confronted with an abundance of information and advertisements promoting a wide range of treatments, medications and alternative therapies. This information is not always easy to navigate for patients and may, in some cases, be misleading. Three new studies presented at the annual AAU meeting in 2019 underscore the need for vigilance of the patient today. These studies will be presented to the media during a special session, hosted by Dr. Stacy Loeb, sure Sunday, May 5, 2019 at 10 hours Dr. Loeb is Assistant Professor of Urology and Population Health at The University of New York and the Manhattan Veterans Affairs Medical Center.
Abstracts presented include:
Publication No. PD34-12
Supplements "stimulating testosterone" The composition and claims are not supported by academic literature
The over-the-counter supplements claiming to increase testosterone levels could be more than satisfying, according to this study, which has evaluated 50 different supplements on the market. The researchers examined each of the product's claims, as well as the active ingredients (components), then examined the recommended daily intake (RDA) and maximum tolerable intake tolerated for each of the ingredients, and reviewed the literature. published by PubMed in support of these allegations. The maximum tolerable intake is the maximum daily intake at which no risk of adverse effects is expected.
The main conclusions include:
- Among the supplements, 111 active ingredients were identified, with each product containing an average of seven active ingredients.
- Prospective data was available for four of the components: fenugreek, shilajit, D-aspartic acid and vitamin D, with only fenugreek and shilajit showing a positive effect on testosterone levels.
- Of the remaining components, four had unsubstantial human data showing a positive effect on testosterone and six of the animal data showed a positive effect.
- In some cases, the supplements contained vitamin and mineral levels above the maximum RDA and sometimes above the maximum tolerable level.
Publication No. MP72-02
Exposure to Cyberknife advertising is badociated with an overestimate of objective benefits over other prostate cancer treatments
Data comparing the use of stereotactic radiotherapy (such as Cyberknife) to other prostate cancer treatment options are limited. Cyberknife's advertising for prostate cancer can be misleading to patients, leading to overestimation of therapeutic benefits. In this study, researchers evaluated the profane impressions of this popular stereotactic radiosurgery when exposed to advertisements in relation to factual information / controls. This survey of 400 men aged 40 to 80 showed that patients exposed to advertisements had a more positive impression of Cyberknife than the control group.
The main conclusions include:
- After reviewing advertisements (with or without disclaimers) or scientific information, respondents indicated that they would choose Cyberknife over other prostate cancer treatments.
- Interviewees in advertising groups were more likely to think Cyberknife was superior to other treatments.
- Respondents who considered the scientific information were less likely to describe Cyberknife as superior to alternative treatments compared to the side effects of erectile dysfunction and incontinence.
Publication No. MP12-18
Attention, buyer: factual evaluation of dietary supplements for nephrolithiasis
A growing number of supplements claiming to reduce – or prevent – the formation of kidney stones are available for over-the-counter patients, but most contain ingredients containing conflicting evidence or no scientific evidence to support these claims. Researchers in Baltimore examined 27 commercially available supplements claiming to dissolve stones, prevent stone formation, reduce the symptoms of stones and support the general health of the kidneys, and reviewed the available medical literature on the effectiveness of the active ingredients contained in each.
The main conclusions include:
- The 27 supplements examined included 56 non-pharmacological active ingredients, only nine of them having published studies on their use in treating computational disease.
- Only 18 ingredient studies were identified, six of which showed mixed or no benefits for computational disease.
- Twelve studies supported the use of ingredients in calculus training, but only five of these studies were studies in humans.
- Of the 27 supplements, 67% contained ingredients with contradictory, refuting or missing evidence of benefit in computational disease.
"The current market is filled with a wealth of information about treatments and services and it can be difficult for patients to determine what is supported by science and what is not." "said Dr. Loeb. "It's more important than ever to talk to your doctor about the supplements you're taking, as well as the advertisements you may see in this promise," the next big thing. "If it sounds too good to be true, Is probably the case. "
About the American Urological Association: Founded in 1902 and based near Baltimore, Maryland, the American Urological Association is one of the leading proponents of the specialty in urology and has more than 22,000 members worldwide. The AUA is a leading urological badociation, providing invaluable support to the community of urologists in the pursuit of its mission to promote the highest standards of urological care through education, research and the formulation of health policies.
SOURCE American Urological Association
Related Links
http://www.AUAnet.org
Source link
